<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00084812</url>
  </required_header>
  <id_info>
    <org_study_id>04-002</org_study_id>
    <secondary_id>MSKCC-04002</secondary_id>
    <nct_id>NCT00084812</nct_id>
  </id_info>
  <brief_title>Safingol and Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors</brief_title>
  <official_title>An Open-Labeled, Non-Randomized Phase I Study of Safingol Administered With Cisplatin in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as cisplatin, work in different ways to stop&#xD;
      tumor cells from dividing so they stop growing or die. Safingol may stop the growth of tumor&#xD;
      cells by blocking the enzymes necessary for their growth and by stopping blood flow to the&#xD;
      tumor.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of safingol when given&#xD;
      with cisplatin in treating patients with locally advanced or metastatic solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the maximum tolerated dose (MTD) of safingol when administered with cisplatin&#xD;
           in patients with locally advanced or metastatic solid tumors.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the toxic effects of this regimen in these patients.&#xD;
&#xD;
        -  Determine the clinical pharmacokinetics of this regimen in these patients.&#xD;
&#xD;
        -  Determine, preliminarily, the therapeutic activity of this regimen in these patients.&#xD;
&#xD;
        -  Determine a safe dose (i.e., near the MTD) for phase II evaluation of this regimen in&#xD;
           these patients.&#xD;
&#xD;
        -  Determine, preliminarily, the role of ceramide and S1P, relative to response and&#xD;
           apoptosis, in patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is an open-label, non-randomized, dose-escalation study of safingol.&#xD;
&#xD;
      Patients receive safingol IV over 1 hour and cisplatin IV over 1 hour on day 1. Courses&#xD;
      repeat every 21 days* in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      NOTE: *Patients receive safingol on days 1 and 8 and cisplatin on day 8 for course 1 only;&#xD;
      course 1 is 28 days in duration.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of safingol until the maximum tolerated dose&#xD;
      (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6&#xD;
      patients experience dose-limiting toxicity. Once the MTD is determined, 10 additional&#xD;
      patients are treated at that dose level.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2004</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recommended phase II dose as assessed by NCI toxicity scale during 3-4 weeks of treatment</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response as assessed by RECIST criteria during 3-6 weeks of treatment</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>Safingol and Cisplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive safingol IV over 1 hour and cisplatin IV over 1 hour on day 1. Courses repeat every 21 days* in the absence of disease progression or unacceptable toxicity.&#xD;
NOTE: *Patients receive safingol on days 1 and 8 and cisplatin on day 8 for course 1 only; course 1 is 28 days in duration.&#xD;
Cohorts of 3-6 patients receive escalating doses of safingol until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, 10 additional patients are treated at that dose level.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <arm_group_label>Safingol and Cisplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>safingol</intervention_name>
    <arm_group_label>Safingol and Cisplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed solid tumor&#xD;
&#xD;
               -  Locally advanced or metastatic disease&#xD;
&#xD;
          -  Refractory to standard therapy OR not amenable to standard therapy&#xD;
&#xD;
          -  No known CNS metastasis or CNS primary&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Karnofsky 70-100%&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 12 weeks&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  WBC count ≥ 3,500/mm^3&#xD;
&#xD;
          -  Hemoglobin ≥ 9.5 g/dL&#xD;
&#xD;
          -  Haptoglobin ≥ 30 mg/dL&#xD;
&#xD;
          -  No concurrent hemolysis or history of non-drug-induced hemolysis (e.g., spherocytosis)&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  AST and ALT ≤ 2.5 times upper limit of normal&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 mg/dL&#xD;
&#xD;
          -  PT and PTT normal&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 1.5 mg/dL&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No cardiac arrhythmias&#xD;
&#xD;
          -  No congestive heart failure&#xD;
&#xD;
          -  No myocardial infarction within the past 6 months&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  No nursing during and for at least 2 months after study participation&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for at least 2 months&#xD;
             after study participation&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No mental incapacity that would preclude giving informed consent&#xD;
&#xD;
          -  No moderate-to-severe high-frequency hearing loss&#xD;
&#xD;
          -  No persistent severe (grade 2) drug-induced peripheral neuropathy&#xD;
&#xD;
          -  No known allergy to cisplatin or any other platinum-containing compound&#xD;
&#xD;
          -  No serious or uncontrolled infection&#xD;
&#xD;
          -  No other medical condition or reason that would preclude study participation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  At least 4 weeks since prior immunotherapy&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  Prior cisplatin allowed&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas and mitomycin)&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Recovered from all prior therapy&#xD;
&#xD;
          -  No concurrent vitamins, antioxidants, herbal preparations, or supplements&#xD;
&#xD;
               -  Concurrent single tablet multivitamin allowed&#xD;
&#xD;
          -  No other concurrent investigational medications&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gary K. Schwartz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Archie N. Tse, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Dickson MA, Carvajal RD, Merrill AH Jr, Gonen M, Cane LM, Schwartz GK. A phase I clinical trial of safingol in combination with cisplatin in advanced solid tumors. Clin Cancer Res. 2011 Apr 15;17(8):2484-92. doi: 10.1158/1078-0432.CCR-10-2323. Epub 2011 Jan 21.</citation>
    <PMID>21257722</PMID>
  </results_reference>
  <verification_date>March 2013</verification_date>
  <study_first_submitted>June 10, 2004</study_first_submitted>
  <study_first_submitted_qc>June 10, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2004</study_first_posted>
  <last_update_submitted>March 21, 2013</last_update_submitted>
  <last_update_submitted_qc>March 21, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 22, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Safingol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

